Market Place
Sourcing Support
Panacea Forms Seismic Pharma For Clinical Heart Failure Portfolio
30 Mar 2026 //
PR NEWSWIRE
Windtree Therapeutics Sells Cardiovascular Biotech Pipeline Drugs
23 Dec 2025 //
GLOBENEWSWIRE
Windtree Therapeutics Signs Letter Of Intent To Acquire CommLoan
03 Dec 2025 //
GLOBENEWSWIRE
Windtree Therapeutics To Receive License Agreement Payments
17 Nov 2025 //
GLOBENEWSWIRE
Windtree Therapeutics Shareholder Approve Revenue Boost Proposals
02 Sep 2025 //
GLOBENEWSWIRE
Windtree’s Istaroxime Picked for Heart Failure Presentation
11 Aug 2025 //
GLOBENEWSWIRE
Windtree`s Istaroxime Phase 2 Interim Analysis Reveals Data
05 Aug 2025 //
GLOBENEWSWIRE
Windtree Therapeutics Reduces Preferred Series C and D Shares
29 Jul 2025 //
GLOBENEWSWIRE
Kraken, Windtree Partner for BNB Custody and Trading Services
22 Jul 2025 //
GLOBENEWSWIRE
Windtree`s $60M BNB Crypto Treasury Strategy Launch
16 Jul 2025 //
GLOBENEWSWIRE
Windtree Receives US Patent for Istaroxime in Acute Heart Failure
02 Jul 2025 //
GLOBENEWSWIRE
Windtree Advances Low-Cost Manufacturing of Phexxi
26 Jun 2025 //
GLOBENEWSWIRE
Windtree to Acquire Environmental Services Business
10 Jun 2025 //
GLOBENEWSWIRE
Windtree Therapeutics Reports Q1 2025 Results and Business Update
16 May 2025 //
GLOBENEWSWIRE
Windtree Therapeutics Complies with Nasdaq Listing Rules
24 Mar 2025 //
GLOBENEWSWIRE
Windtree Reports Ph 2b Results For Istaroxime In Heart Failure
30 Sep 2024 //
GLOBENEWSWIRE
Despite cash infusion, Windtree still faces money running out within a year
21 Aug 2024 //
FIERCE BIOTECH
Windtree Updates On Istaroxime Development And Upcoming Trial Data
25 Jul 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Closes Private Placement Of Series C Preferred Stock
22 Jul 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Regains Compliance with Nasdaq
07 May 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Announces Reverse Stock Split
18 Apr 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Reports Q4 2023 and Year-End Results
17 Apr 2024 //
GLOBENEWSWIRE
Windtree Acquires Early-Stage, Oncology Platform and Completes $1.5M Financing
08 Apr 2024 //
GLOBENEWSWIRE
Windtree Renews Agreement with Chang Gung University
01 Feb 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Announces Engagement of Strategic Advisor
31 Jan 2024 //
GLOBENEWSWIRE
Windtree Eliminates $15M Contingent Liability to Deerfield Management Company
25 Jan 2024 //
GLOBENEWSWIRE
Windtree Therapeutics Announces License Agreement with Lee™s Pharmaceuticals
17 Jan 2024 //
GLOBENEWSWIRE
Windtree hands over more licensing rights to Lee’s Pharma
17 Jan 2024 //
FIERCE BIOTECH
Windtree Announces Reduction In Arrythmias In A New Study With Istaroxime
02 Jan 2024 //
GLOBENEWSWIRE
Windtree Announces the Start of Patient Dosing In Phase 2 Study of Istaroxime
18 Dec 2023 //
GLOBENEWSWIRE
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
16 Nov 2023 //
GLOBENEWSWIRE
Windtree Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
08 Nov 2023 //
GLOBENEWSWIRE
Windtree to Present at ThinkEquity Conference on October 19th in New York City
12 Oct 2023 //
GLOBENEWSWIRE
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference
10 Oct 2023 //
GLOBENEWSWIRE
Windtree to Present at Dawson James Small Cap Growth Conference on October 12th
03 Oct 2023 //
GLOBENEWSWIRE
Windtree Announces Issuance of Composition of Matter Patent for SERCA2a
23 Aug 2023 //
GLOBENEWSWIRE
Windtree Therapeutics Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Windtree faces Catch-22 conundrum for hypertension med
05 Jul 2023 //
FIERCE BIOTECH
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
27 Jun 2023 //
GLOBENEWSWIRE
Windtree Announces Notice of Allowance from the US Patent
12 Jun 2023 //
GLOBENEWSWIRE
Windtree Therapeutics to Host Investor Day Focusing on Cardiogenic Shock Market
05 Jun 2023 //
GLOBENEWSWIRE
Windtree Therapeutics Reports 1Q 2023 FYR & Provides Key Business Updates
15 May 2023 //
GLOBENEWSWIRE
Windtree Announces Pub Its SEISMiC Pre Shock Study Comparing 2 dose Istaroxime
27 Apr 2023 //
GLOBENEWSWIRE
Windtree Announces Closing of $12.42 Million Underwritten Public Offering
24 Apr 2023 //
GLOBENEWSWIRE
Windtree Therapeutics Announces Pricing of Upsized $10.8 M Underwritten PO
20 Apr 2023 //
GLOBENEWSWIRE
Why Windtree Therapeutics Stock Is Tumbling Today
20 Apr 2023 //
BENZINGA
Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2
17 Apr 2023 //
GLOBENEWSWIRE
Windtree Reports Fourth Quarter and Year-End 2022 Financial Results
03 Apr 2023 //
GLOBENEWSWIRE
Windtree Regains Compliance with Nasdaq
13 Mar 2023 //
GLOBENEWSWIRE
Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care
06 Mar 2023 //
GLOBENEWSWIRE
Windtree Announces Publication on its SERCA2a Activator Drug Candidate
28 Feb 2023 //
GLOBENEWSWIRE
Windtree Announces Istaroxime Abstract Has Been Accepted at Conference
27 Feb 2023 //
GLOBENEWSWIRE
Windtree Announces Issuance of Istaroxime Patent from U.S. Patent
24 Feb 2023 //
GLOBENEWSWIRE
Windtree Therapeutics Announces Reverse Stock Split
23 Feb 2023 //
GLOBENEWSWIRE
Windtree to Raise $1.0M From the Exercise of Previously Issued Warrants
20 Jan 2023 //
GLOBENEWSWIRE
Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance
05 Dec 2022 //
GLOBENEWSWIRE
Windtree Therapeutics Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Windtree Announces Notice of Allowance from the US Patent
25 Oct 2022 //
GLOBENEWSWIRE
Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study
28 Sep 2022 //
GLOBENEWSWIRE
